GlassScriptPhysician profile
Lori Eve Long
NPI 1912270265
$979.87
in general payments reported to CMS, 2019-2025
14 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.08 · 2022: $147 · 2023: $205 · 2024: $252 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.13 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $189.67 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $151.26 | 2022-2024 | |
| Novo Nordisk INC | $105.07 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.84 | 2021-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $77.26 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $77.12 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $57.58 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $52.03 | 2025 | Repatha, Otezla |
| Paratek Pharmaceuticals, INC. | $44.50 | 2024-2025 | Nuzyra |
| Pfizer INC. | $36.92 | 2021-2025 | |
| Axsome Therapeutics, INC. | $32.44 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $20.86 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.32 | 2025 | Voquezna |
| Medtronic, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.